KRRO
Korro Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.13
+4.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.4M | 6.4M | 2.3M | — | — |
| Cost of Revenue | 649.0K | 4.3M | — | — | — |
| Gross Profit | 1.7M | 2.1M | 2.3M | — | — |
| Operating Expenses | |||||
| R&D Expense | 51.3M | 65.6M | 63.6M | 57.3M | 42.2M |
| SG&A Expense | 26.7M | 28.2M | 30.5M | 36.5M | 16.8M |
| General & Admin Expense | 26.7M | 28.2M | 30.5M | 24.0M | 16.8M |
| Selling & Marketing Expense | — | — | — | 12.5M | — |
| Other Expenses | (649.0K) | (4.3M) | — | (9.3M) | — |
| Total Operating Expenses | 77.4M | 89.5M | 94.2M | 84.5M | 59.0M |
| Cost and Expenses | 78.0M | 93.7M | 94.2M | 84.5M | 59.0M |
| Operating Income (EBIT) | (75.7M) | (87.3M) | (91.9M) | (84.5M) | (59.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 947.0K |
| Interest Expense | — | — | — | — | 118.0K |
| Net Interest Income | — | — | — | — | 829.0K |
| Other Non-Op Income/Expense | (30.1M) | (29.3M) | 8.5M | 3.4M | 976.0K |
| Non-Operating Income (excl Interest) | (1.2M) | — | — | — | — |
| EBT (Pre-Tax Income) | (105.8M) | (116.6M) | (83.4M) | (81.1M) | (58.0M) |
| Income Tax Expense | 839.0K | 637.0K | 141.0K | 27.0K | 10.0K |
| Bottom Line | |||||
| Net Income | (106.6M) | (117.3M) | (83.6M) | (81.2M) | (58.0M) |
| Earnings from Cont. Ops | (106.6M) | (117.3M) | (83.6M) | (81.2M) | (58.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (106.6M) | (117.3M) | (83.6M) | (81.2M) | (58.0M) |
| Per Share | |||||
| Basic EPS | ($10.01) | ($12.48) | ($9.37) | ($53.09) | ($227.58) |
| Diluted EPS | ($10.01) | ($12.48) | ($9.37) | ($53.08) | ($227.42) |
| Revenue Per Share | $0.14 | $0.68 | $0.25 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 17.6M | 9.4M | 8.9M | 1.5M | 255000 |
| Diluted Shares Outstanding | 17.6M | 9.4M | 8.9M | 1.5M | 255174 |
| Profitability Metrics | |||||
| EBITDA | (71.9M) | (83.1M) | (88.3M) | (80.9M) | (56.5M) |
| D&A | 2.6M | 4.3M | 3.6M | 3.6M | 2.5M |
| EBIT | (74.5M) | (87.3M) | (91.9M) | (84.5M) | (59.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026